Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M-O Grimm

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Der Urologe. Ausg. A|April 30, 2016
[Comment on: Focal therapy for small renal masses. Observation, ablation or surgery]M-O Grimm
Aktuelle Urologie|September 30, 2016
[Immunooncology in Urologic Cancers: Current Status]M-O Grimm
Urologie (Heidelberg, Germany)|June 29, 2023
[New drug therapy]M-O Grimm, H Kübler
The Journal of Urology|November 11, 2005
Transurethral resection of superficial bladder cancer: technically safe, oncologically anything but perfectM O Grimm, R Ackermann
Der Urologe. Ausg. A|May 6, 2016
[Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition]H Oppel-Heuchel, M-O Grimm
Aktuelle Urologie|November 24, 2020
H Rexer, M-O Grimm, T Steiner
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 29, 2025
Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planningM-O Grimm, K Leucht, A Stenzl
Der Urologe. Ausg. A|August 17, 2014
[Differential diagnosis of hematuria]M Horstmann, T Franiel, M O Grimm
Der Urologe. Ausg. A|September 25, 2008
[Value of lymphadenectomy for limited nodal recurrence of prostate cancer after local therapy with curative intent]I Wolff, M-O Grimm, M Wirth
Aktuelle Urologie|December 8, 2017
H Rexer, M Graefen, M-O Grimm
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Der Urologe. Ausg. A|April 30, 2016
[Comment on: Focal therapy for small renal masses. Observation, ablation or surgery]M-O Grimm
Aktuelle Urologie|September 30, 2016
[Immunooncology in Urologic Cancers: Current Status]M-O Grimm
Urologie (Heidelberg, Germany)|June 29, 2023
[New drug therapy]M-O Grimm, H Kübler
The Journal of Urology|November 11, 2005
Transurethral resection of superficial bladder cancer: technically safe, oncologically anything but perfectM O Grimm, R Ackermann
Der Urologe. Ausg. A|May 6, 2016
[Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition]H Oppel-Heuchel, M-O Grimm
Aktuelle Urologie|November 24, 2020
H Rexer, M-O Grimm, T Steiner
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 29, 2025
Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planningM-O Grimm, K Leucht, A Stenzl
Der Urologe. Ausg. A|August 17, 2014
[Differential diagnosis of hematuria]M Horstmann, T Franiel, M O Grimm
Der Urologe. Ausg. A|September 25, 2008
[Value of lymphadenectomy for limited nodal recurrence of prostate cancer after local therapy with curative intent]I Wolff, M-O Grimm, M Wirth
Aktuelle Urologie|December 8, 2017
H Rexer, M Graefen, M-O Grimm
Pageof 6